Clinical trial
Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast…
NCT00479856 · GlaxoSmithKline, Industry · Terminated
Key facts
| NCT number | NCT00479856 |
|---|---|
| Title | Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer |
| Official title | An Open-label, Multi-centre Study of Lapatinib in Combinationwith Chemotherapy in Patients With ErbB2 Overexpressing Breastcancer After Trastuzumab Failure in the Neoadjuvant or Adjuvantsetting. |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Relapsed Breast Cancer, Neoplasms, Breast |
| Intervention type | Drug |
| Interventions | Lapatinib, Capecitabine, Docetaxel, nab-Paclitaxel |
| Enrollment | 9 |
| Start date | Nov 1, 2007 |
| Primary completion | Sep 1, 2009 |
| Completion | Mar 1, 2010 |
| First posted | May 28, 2007 |
| Last update posted | Jun 5, 2012 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: